Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients
TRANSFUSION AND APHERESIS SCIENCE, cilt.60, sa.4, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 60 Sayı: 4
- Basım Tarihi: 2021
- Doi Numarası: 10.1016/j.transci.2021.103159
- Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
- Anahtar Kelimeler: Chemomobilization, Cyclophosphamide, Filgrastim, Multiple myeloma, Autologous stem cell transplantation, STEM-CELL MOBILIZATION, COLONY-STIMULATING FACTOR, HIGH-DOSE CYCLOPHOSPHAMIDE, BLOOD PROGENITOR CELLS, LENALIDOMIDE THERAPY, INDUCTION THERAPY, TRANSPLANTATION, COLLECTION, IMPACT, CHEMOTHERAPY
- İnönü Üniversitesi Adresli: Evet
Özet
Background and objective: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment approach in most multiple myeloma (MM) patients. Before ASCT, chemomobilization or only granulocyte-colony stimulating factor (G-CSF) mobilization can be preferred in stem cell mobilization. The primary aim of the study is to compare the effect of the two mobilization regimens on hematopoietic engraftment times, CD34+cell counts and number of apheresis required to harvest stem cells.